Clinical application of functional glycoproteomics - Dissection of glycotopes carried by soluble CD44 variants in sera of patients with cancers

Proteomics

Volumn 8, Issue 16, 2008, Pages 3263-3273

  Lim, Khe Ti ^a   Miyazaki, Keiko ^a   Kimura, Naoko ^a   Izawa, Mineko ^a   Kannagi, Reiji ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Functional glycoproteomics; Glycotope; Hematogenous metastasis; Sialyl Lewis a; Sialyl Lewis x

Indexed keywords

CD44V ANTIGEN; HYALURONIC ACID; METALLOPROTEINASE; SELECTIN; SIALYL LEWIS X ANTIGEN;

ANTIGEN DETECTION; ANTIGEN FUNCTION; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER PATIENT; GLYCOBIOLOGY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SERUM;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIGENS, CD44; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOMICS; GLYCOPROTEINS; HUMANS; IMMUNOPRECIPITATION; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 50449087746     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800147     Document Type: Review

References (48)

1. Kannagi, R., Yin, J., Miyazaki, K., Izawa, M., Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomori's concepts revisited. Biochim. Biophys. Acta 2008, 1780, 525-531.
2. Kannagi, R., Carbohydrate antigen sialyl Lewis a - its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med. J. 2007, 30, 189-209.
3. Kannagi, R., Izawa, M., Koike, T., Miyazaki, K. et al., Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004, 95, 377-384.
4. Kannagi, R., Fukushi, Y., Tachikawa, T., Noda, A. et al., Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. Cancer Res. 1986, 46, 2619-2626.
5. Kannagi, R., Kitahara, A., Itai, S., Zenita, K. et al., Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing epitopes consisting of sialyl or sialyl-fucosyl type 1 chain. Cancer Res. 1988, 48, 3856-3863.
6. Kaufmann, M., Heider, K. H., Sinn, H. P., von Minckwitz, G. et al., CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995, 345, 615-619.
7. Naor, D., Sionov, R. V., Ish-Shalom, D., CD44: Structure, function, and association with the malignant process. Adv. Cancer Res. 1997, 71, 241-319.
8. Gotte, M., Yip, G. W., Heparanase, hyaluronan, and CD44 in cancers: A breast carcinoma perspective. Cancer Res. 2006, 66, 10233-10237.
9. Hill, A., McFarlane, S., Johnston, P. G., Waugh, D. J., The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett. 2006, 237, 1-9.
10. Bajorath, J., Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 2000, 39, 103-111.
11. Kannagi, R., Goto, Y., Fukui, F., In search of the carbohydrate structures on CD44 critical for hyaluronic acid binding - roles of sialylation and sulfation. Trends Glycosci. Glycotechnol. 2004, 16, 211-223.
12. Hanley, W. D., Burdick, M. M., Konstantopoulos, K., Sackstein, R., CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res. 2005, 65, 5812-5817.
13. Hanley, W. D., Napier, S. L., Burdick, M. M., Schnaar, R. L. et al., Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells. FASEB J. 2006, 20, 337-339.
14. Bistrup, A., Bhakta, S., Lee, J. K., Belov, Y. Y. et al., Sulfotransferases of two specificities function in the reconstitution of high-endothelial-cell ligands for L-selectin. J. Cell Biol. 1999, 145, 899-910.
15. Weston, B. W., Smith, P. L., Kelly, R. J., Lowe, J. B., Molecular cloning of a fourth member of a human α (1, 3)fucosyltransferase gene family. Multiple homologous sequences that determine expression of the Lewis x, sialyl Lewis x, and difucosyl sialyl Lewis x epitopes. J. Biol. Chem. 1992, 267, 24575-24584.
16. Kimura, N., Ohmori, K., Miyazaki, K., Izawa, M. et al., Human B-lymphocytes express α 2-6 sialylated 6-sulfo-N-acetyllactosamine serving as a preferred ligand for CD22/siglec-2. J. Biol. Chem. 2007, 282, 32200-32207.
17. a expression on human colon cancers. Cancer Res. 2004, 64, 4498-4505.
18. Mitsuoka, C., Sawada-Kasugai, M., Ando-Furui, K., Izawa, M. et al., Identification of a major carbohydrate capping group of the L-selectin ligand on high endothelial venules in human lymph nodes as 6-sulfo sialyl Lewis x. J. Biol. Chem. 1998, 273, 11225-11233.
19. Kimura, N., Mitsuoka, C., Kanamori, A., Hiraiwa, N. et al., Reconstitution of functional L-selectin ligands on a cultured human endothelial cell line by co-transfection of α1 → 3 fucosyltransferase VII and newly cloned GlcNAcβ: 6-Sulfotransferase cDNA. Proc. Natl. Acad. Sci. USA 1999, 96, 4530-4535.
20. Izawa, M., Kumamoto, K., Mitsuoka, C., Kanamori, A. et al., Expression of sialyl 6-sulfo Lewis x is inversely correlated with conventional sialyl Lewis x expression in human colorectal cancer. Cancer Res. 2000, 60, 1410-1416.
21. Maiti, A., Maki, G., Johnson, P., TNF-α induction of CD44-mediated leukocyte adhesion by sulfation. Science 1998, 282, 941-943.
22. Delcommenne, M., Kannagi, R., Johnson, P., TNF-α increases the carbohydrate sulfation of CD44: Induction of 6-sulfo N-acetyl lactosamine on N- and O-linked glycans. Glycobiology 2002, 12, 613-622.
23. Tjew, S. L., Brown, K. L., Kannagi, R., Johnson, P., Expression of N-acetylglucosamine 6-0 sulfotransferases (GlcNAc6STs) -1 and -4 in human monocytes: GlcNAc6ST-1 is implicated in the generation of the 6-sulfo N-acetyllactosamine/Lewis x epitope on CD44 and is induced by TNF-α. Glycobiology 2005, 15, 7C-13C.
24. Okamoto, I., Kawano, Y., Murakami, D., Sasayama, T. et al., Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J. Cell Biol. 2001, 155, 755-762.
25. 2+ influx and PKC activation. J. Cell Biol. 2004, 165, 893-902.
26. Nagano, O., Saya, H., Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004, 95, 930-935.
27. Kannagi, R., Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj. J. 1997, 14, 577-584.
28. Kitayama, J., Tsuno, N., Sunami, E., Osada, T. et al., E-selectin can mediate the arrest type of adhesion of colon cancer cells under physiological shear flow. Eur. J. Cancer 2000, 36, 121-127.
29. Kyogashima, M., Tamiya-Koizumi, K., Ehara, T., Li, G. et al., Rapid demonstration of diversity of sulfatide molecular species from biological materials by MALDI-TOF MS. Glycobiology 2006, 16, 719-728.
30. Zhuo, L., Kanamori, A., Kannagi, R., Itano, N. et al., SHAP potentiates the CD44-mediated leukocyte adhesion to the hyaluronan substratum. J. Biol. Chem. 2006, 281, 20303-20314.
31. Pelletier, L., Guillaumot, P., Freche, B., Luquain, C. et al., Gamma-secretase-dependent proteolysis of CD44 promotes neoplastic transformation of rat fibroblastic cells. Cancer Res. 2006, 66, 3681-3687.
32. Kopp, R., Classen, S., Wolf, H., Gholam, P. et al., Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res. 2001, 21, 2995-3000.
33. Sheen-Chen, S. M., Chen, W. J., Eng, H. L., Sheen, C. C. et al., Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer. Cancer Invest. 1999, 17, 581-585.
34. Yamane, N., Tsujitani, S., Makino, M., Maeta, M. et al., Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer. Oncology 1999, 56, 232-238.
35. Saito, H., Tsujitani, S., Katano, K., Ikeguchi, M. et al., Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 1998, 83, 1094-1101.
36. Yamaguchi, A., Goi, T., Taguchi, S., Ohtaki, N. et al., Clinical significance of serum levels of CD44 variant exons 8-10 protein in colorectal cancer. J. Gastroenterol. 1998, 33, 349-353.
37. Gadducci, A., Ferdeghini, M., Fanucchi, A., Annicchiarico, C. et al., Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer. Anticancer Res. 1997, 17, 4463-4466.
38. Goi, T., Yamaguchi, A., Seki, K., Nakagawara, G. et al., Soluble protein encoded by CD44 variant exons 8-10 in the serum of patients with colorectal cancer. Br. J. Surg. 1997, 84, 1452-1453.
39. Sliutz, G., Tempfer, C., Winkler, S., Kohlberger, P. et al., Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br. J. Cancer 1995, 72, 1494-1497.
40. Kittl, E. M., Ruckser, R., Selleny, S., Samek, V. et al., Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients. Exp. Clin. Immunogenet. 1997, 14, 264-272.
41. Kittl, E. M., Haberhauer, G., Ruckser, R., Selleny, S. et al., Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatol. Int. 1997, 16, 181-186.
42. Scott, D. A., Stapleton, J. A., Palmer, R. M., Wilson, R. F. et al., Plasma concentrations of reputed tumor-associated soluble CD44 isoforms (v5 and v6) in smokers are dose related and decline on smoking cessation. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 1211-1214.
43. Gansauge, F., Gansauge, S., Rau, B., Scheiblich, A. et al., Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma. Cancer 1997, 80, 1733-1739.
44. De Marzo, A. M., Bradshaw, C., Sauvageot, J., Epstein, J. I. et al., CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture. Prostate 1998, 34, 162-168.
45. Zeimet, A. G., Widschwendter, M., Uhl-Steidl, M., Muller-Holzner, E. et al., High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br. J. Cancer 1997, 76, 1646-1651.
46. Foekens, J. A., Dall, P., Klijn, J. G., Skroch-Angel, P. et al., Prognostic value of CD44 variant expression in primary breast cancer. Int. J. Cancer 1999, 84, 209-215.
47. Isozaki, H., Ohyama, T., Mabuchi, H., Expression of cell adhesion molecule CD44 and sialyl Lewis A in gastric carcinoma and colorectal carcinoma in association with hepatic metastasis. Int. J. Oncol. 1998, 13, 935-942.
48. Yamaguchi, A., Goi, T., Seki, K., Ohtaki, N. et al., Clinical significance of combined immunohistochemical detection of CD44v and sialyl LeX expression for colorectal cancer patients undergoing curative resection. Oncology 1998, 55, 400-403.